Seeking Alpha

Shares of Ligand Pharmaceuticals (LGND +13.9%) are soaring since being removed from a a trading...

Shares of Ligand Pharmaceuticals (LGND +13.9%) are soaring since being removed from a a trading halt earlier this morning. The stock was halted after its partner GlaxoSmithKline (GSK +1%) announced the FDA has approved Promacta for the treatment of thrombocytopenia - a condition in patients with chronic hepatitis C that causes low blood platelet counts - which will allow them to initiate and maintain interferon-based therapy.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector